

# SolasCure

BRAIN Capital Markets Day

**Dr. Sam Bakri, Executive Chairman**  
**SolasCure**

**Revolutionizing Wound Care**

---

---

---

# Safe Harbor Statement

---

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of September 15th, 2020. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.



# SolasCure empowers wound care professionals with disruptive, better, lower-cost tools

Founded: 2017

Funded: 2018


Funding to date: over £10 million

FTEs: 10

JV partners: BRAIN Biotech; EVA Pharma

Collaborators: Fraunhofer, URGO (2019 prize winner)

## Timeline for Aurase development



# Chronic wounds are a growing global problem, with imperfect solutions

- Chronic wounds tend to fall into three categories:
  - Venous leg ulcers
  - Diabetic foot ulcers
  - Pressure ulcers
- Worldwide prevalence of chronic wounds is growing rapidly as populations age and grow more obese
  - Chronic wounds (not healing after three months) are caused by factors such as poor circulation, neuropathy, mobility and infection
  - Slough, necrotic tissue and biofilm all slow healing

Global Chronic Wounds	Growth Rate	Average Care Cost / Time
40 mm	8%	\$14k / 14 weeks

Global Cost of Chronic Wound Care Complications

**\$30 bn**

"Wounds are an under recognised and poorly managed modern health care problem that consumes ~10% of health care expenditure in many countries."  
- Prof. Keith Harding



Sources: MedMarket Diligence LLC. AI Gill Group Research.

4

# Debridement, removal of dead tissue & foreign objects, is a necessary step for healing



## Autolytic (moist dressings)

- Slow, low-cost products
- High patient care costs due to longer care time



## Surgical / manual

- Aggressive and unsuitable for fragile patients
- Requires highly-trained personnel & expensive materials



## Enzymatic

- SANTYL sales of ~\$350m
- Clear unmet need



## Maggot therapy

- Effective, and similar cost to enzymatic therapy
- Logistically complex and unpopular with healthcare personnel and patients




# Aurase is an innovative gel-based product that efficiently & gently cleans wounds

SolasCure's first product, Aurase, is a hydrogel containing a highly-specific fibrinolytic enzyme, isolated and cloned from maggots

- Permits the use of the main maggot-derived wound debriding enzyme without the cost or labour input involved with the use of live maggots
- Augments and synergises the body's own wound cleansing processes

We expect that these properties will have several key clinical benefits:

- Specific swift destabilisation of fibrin debris
- No irritation or damage to healthy tissue
- Reducing the time to full debridement without delaying wound healing



# Aurase demonstrates superiority to competition across several key areas

	Surgery	Hydrogel	Maggots	Enzymatic Debridement		
				Santyl	EscharEx	Aurase
Efficacy						
Safety / Pain						
Patient Care Cost						
Convenience						

---

# SolasCure assembled a world-class team

---



**Dr. Sam Bakri**  
Executive Chairman

Sam is a serial healthcare entrepreneur. He was the CEO and co-founder of Kind Consumer, a UK based medical technology company, the co-founder of AIDA Health (backed by Mayo Clinic) and Gelmetix Limited.



**Benjamin Newmark**  
President & Chief Financial Officer

Benjamin has held leadership roles at various early-stage and growth startups in the healthcare and financial technology spaces.



**Frank Goebel**  
Chief Business Officer

Frank is the former CFO of BRAIN. He previously spent 15 years in Structured Finance at a global investment bank.



**Lily Bouzelmat**  
Chief Development Officer

Lily is a trained biologist and has led global Phase I to III clinical studies in various therapeutic areas in multiple biotechnology companies in the US.



**Prof. David Goldsmith**  
Chief Medical Officer

David is a former Consultant Nephrologist at Guy's & St Thomas' NHS Foundation Trust Hospital. Academic positions include Cardio-Renal Medicine and King's College London.



**Dr. Bela Kelety**  
Chief Technology Officer

Bela is Manager Strategic Projects at BRAIN where he led early R&D on Aurase. He previously cofounded a successful biotech company and has a PhD in biochemistry from the Max Planck Institute.



**Chris Stephenson**  
Strategy

Chris is the VP of Research & Development at Acelity (now part of 3M). He previously held leadership roles at Crawford Medical, Lantor and Smith & Nephew.

---

## And a board with a wealth of experience

---



**Dr. Sam Bakri**  
Executive Chairman  
Sam is a serial healthcare entrepreneur. He was the CEO and co-founder of Kind Consumer, a UK based medical technology company, the co-founder of AIDA Health (backed by Mayo Clinic) and Gelexir Healthcare, where he is Vice Chairman.



**Adriaan Moelker**  
Director  
Adriaan is the CEO of BRAIN. Before joining BRAIN, he held a wide variety of management positions during his 30-year career, and his particular focus has been on Biotechnology.



**Dr. Charles Bruce**  
Director  
Charles is Associate Medical Director for Mayo Clinic Ventures. He is Professor of Medicine in the Division of Cardiovascular Diseases, Mayo Clinic College of Medicine.



**Francois Fournier**  
Director  
François is CEO & President of Virbac. He is the former head of Asia-Pac at Smith & Nephew. He formerly held roles at Abbott and Galderma/Nestlé Skin Health.



**Frank Goebel**  
Director  
Frank is the former CFO of BRAIN. He previously spent 15 years in Structured Finance at a global investment bank.



**Riad Armanious**  
Director  
Riad is the CEO of Eva Pharma, one of the leading specialty pharma companies in Africa. Riad is active in the YPO (Young Presidents Association), the "T20" foundation and Vice chairman in the Egyptian Industrial Chamber of Pharmaceuticals.



**Dan Wright**  
Director  
Dan was a founding partner and COO of NorthEdge Capital, a U.K. mid-market buyout firm focused on investments in the North of England.

## And has attracted an expert set of advisors, investors & partners

### Medical Advisory Board Chairs



Dr. Robert Kirsner  
US Medical Advisory Board Chair  
Harvey Blank Chair in Dermatology at the University of Miami.  
Former Boards of Wound Healing Society & Association for the Advancement of Wound Care

"Aurase could be the new gold standard in wound care."



Prof. Keith Harding  
EU Medical Advisory Board Chair  
Director of WWIC and Head of the Wound Healing Research Unit at Cardiff University. Clinical Lead for Wound Healing in the Cardiff & Vale University Health Board.

"The technology that SolasCure is developing has the potential to produce an effective, practical and easy to use new method of achieving an important goal in treating patients with wounds and benefiting large numbers of patients."

### Select clinical trial partners\*



### Institutional support



Winner  
2019  
URGO  
Prize



\* Clinical trial start pending.

---

## SolasCure benefits from the expertise & resources of key collaborative partners

---



CHARACTERISED  
MICROORGANISMS  
**53,000**

EMPLOYEES  
**120**

- BRAIN is one of Europe's leading technology companies in the field of industrial or "white" biotechnology
- BRAIN harnesses biological diversity to develop innovative solutions and products for successful applications in chemistry and in the cosmetics and food industries
- BRAIN spun Aurase out to SolasCure to further development



EMPLOYEES  
**3,000**

COUNTRIES  
**42**

- EVA Pharma is one of the leading pharmaceutical companies in the MENA region
- 165 pharmaceutical products cover various therapeutic categories including: Neurology, Psychiatry, Cardiovascular, Orthopedics, GIT, Pediatrics, Urology, and Dermatology
- EVA made a significant strategic investment into SolasCure in 2019


## SolasCure is looking to develop a suite of evidence based wound care products

	Formulation	Biofilm	Diagnostic	Other
Collaborators	 	 	 WELSH WOUND INNOVATION ARLOESODD CLWYFFAU CYMRU	Top Tier Academic Medical Centre
Key Points	Optimised handling	Investigating various actions	Collaborative research initiated into biomarker discovery	Initiating discussion

---

## SolasCure has a broad shareholder base

---



---

## **SolasCure** has a variety of long-term exit options including

---

- Strategic sale after collecting in human data from Phase 2 / 3 trials
- Full licensing deal with an upfront payment, milestone payments and a royalty
- Geographic licensing deals, or joint ventures



---

# Thank you for your attention

---

BRAIN Aktiengesellschaft  
Darmstädter Straße 34–36  
64673 Zwingenberg, Germany  
[www.brain-biotech.com](http://www.brain-biotech.com)

Your contacts:

Michael Schneiders, Head of IR  
+49 (0) 6251-9331-86  
[MiS@brain-biotech.com](mailto:MiS@brain-biotech.com)

Martina Schuster, IR  
+49 (0) 6251-9331-69  
[MS@brain-biotech.com](mailto:MS@brain-biotech.com)

